Search

Search Constraints

You searched for: Author/Creator Lanctot, Krista L.

Search Results

1. [O1–01–06]: MEASURING APATHY IN ALZHEIMER'S DISEASE IN THE APATHY IN DEMENTIA METHYLPHENIDATE TRIAL 2 (ADMET 2): A COMPARISON OF INSTRUMENTS. (1st July 2017)

2. [P2–219]: INFLAMMATION MEDIATES THE IMPACT OF SMALL‐VESSEL DISEASE ON COGNITION IN ALZHEIMER'S DISEASE: EVIDENCE FROM A MULTIMODAL STRATIFIED COHORT STUDY. (1st July 2017)

3. [P3–210]: PLASMA SPHINGOLIPID RATIOS AND VERBAL MEMORY PERFORMANCE IN A CORONARY ARTERY DISEASE POPULATION AT RISK FOR VASCULAR COGNITIVE IMPAIRMENT (VCI) AND ALZHEIMER's DISEASE. (1st July 2017)

4. [P3–239]: A LIPIDOMICS APPROACH TO ASSESS PLASMA SPHINGOLIPIDS AS PREDICTORS OF VERBAL MEMORY PERFORMANCE IN CORONARY ARTERY DISEASE PATIENTS UNDERTAKING CARDIAC REHABILITATION: A C18:0 SIGNATURE FOR COGNITIVE RESPONSE TO EXERCISE. (1st July 2017)

5. [P4–003]: A RANDOMIZED, PLACEBO‐CONTROLLED, CROSS‐OVER TRIAL INVESTIGATING NABILONE AS A TREATMENT FOR AGITATION IN PATIENTS WITH MODERATE‐TO‐SEVERE ALZHEIMER'S DISEASE: BLINDED, INTERIM SAFETY RESULTS. (1st July 2017)

7. Angiotensin receptor blockers versus angiotensin‐converting enzyme inhibitors: Longitudinal associations with PET amyloid in the Alzheimer's Disease Neuroimaging Initiative: Neuroimaging / evaluating treatments. (7th December 2020)

8. Biomarkers of agitation in moderate‐to‐severe Alzheimer's disease patients enrolled in an RCT with nabilone: Biomarkers (non‐neuroimaging) / plasma/serum/urine biomarkers. (7th December 2020)

9. F4‐02‐04: NABILONE SIGNIFICANTLY IMPROVES AGITATION/AGGRESSION IN PATIENTS WITH MODERATE‐TO‐SEVERE AD: PRELIMINARY RESULTS OF A PLACEBO‐CONTROLLED, DOUBLE‐BLIND, CROSS‐OVER TRIAL. (1st July 2006)

10. How much can the Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS‐Cog) tell us? Insights from a latent state‐trait auto‐regressive (LST‐AR) model: Neuropsychology/Neuropsychological profiles of dementia: Valid biomarkers?. (7th December 2020)